Increlex Global Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The increlex market research report is one of a series of new reports that provides increlex market statistics, including the increlex industry's global market size, regional shares, competitors with an increlex market share, detailed increlex market segments, market trends and opportunities, and any further data you may need to thrive in the increlex industry. This increlex market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The growth in the forecast period can be attributed to rising demand for effective treatments for growth hormone insensitivity, increasing adoption of personalized medicine, rising clinical trials to expand therapeutic applications, rising regulatory approvals for innovative formulations, growing healthcare infrastructure in emerging economies, and rising awareness about pediatric growth disorders globally. Major trends in the forecast period include advancements in recombinant DNA technology, improvement in delivery systems for subcutaneous injections, advancements in patient monitoring solutions, integration of telemedicine for patient follow-up, and advancements in drug delivery systems.

The growing prevalence of childhood-onset growth hormone deficiency (CGHD) is expected to drive the growth of the increlex market. CGHD occurs when the body does not produce enough growth hormone during childhood, resulting in slower growth and shorter stature. Factors such as advancements in diagnostic methods and increased awareness of the condition have contributed to the rise in CGHD cases. As awareness and diagnosis of CGHD increase, the demand for Increlex, a synthetic IGF-1 treatment, is also growing, as more children are receiving the necessary therapy. For example, in November 2023, the Council of Health Insurance in Saudi Arabia estimated that childhood-onset growth hormone deficiency affects between 1 in 3,500 and 1 in 10,000 children, with boys being more commonly affected. This increase in CGHD prevalence is driving the expansion of the increlex market.

Rising healthcare expenditure is anticipated to propel the growth of the increlex market as well. Healthcare expenditure refers to the total financial resources spent on medical services, treatments, medications, and hospital care over a specific period. Factors such as an aging population, increased healthcare needs, advancements in medical technology, and rising service and medication costs are contributing to the rise in healthcare spending. As healthcare expenditure increases, access to advanced treatments such as increlex becomes more widely available, further driving market growth. For instance, a report from the Office for National Statistics in May 2024 showed a 5.6% increase in total healthcare expenditure in the UK from 2022 to 2023, compared to a mere 0.9% growth in 2022. This rising healthcare expenditure is expected to boost the increlex market.

In October 2024, Eton Pharmaceuticals Inc., a US-based pharmaceutical company, acquired increlex (mecasermin injection) from Ipsen S.A. for an undisclosed amount. Ipsen will continue to distribute Increlex for six months before Eton assumes responsibility for global commercialization. This acquisition will allow Eton to expand its portfolio while ensuring that access to Increlex remains uninterrupted. Ipsen S.A., a pharmaceutical company based in France, specializes in the development of drugs such as Increlex.

The key company operating in the increlex market is Ipsen S.A.

North America was the largest region in the increlex market in 2024. The regions covered in increlex report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the increlex market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Increlex is the brand name for mecasermin, a recombinant human insulin-like growth factor-1 (rhIGF-1). It is used to treat growth failure in children with severe primary IGF-1 deficiency or those whose bodies do not produce enough insulin-like growth factor-1 (IGF-1), a crucial hormone for normal growth.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The primary age group for Increlex includes infants, toddlers, and children aged 5-12 years. Pediatric patients diagnosed with severe primary IGF-1 deficiency (SPIGFD), a rare growth disorder where the body lacks sufficient IGF-1 despite having adequate growth hormone levels, are the main users of Increlex. Mecasermin works by mimicking IGF-1 to address this deficiency, helping to improve growth rates and other developmental outcomes. Increlex is distributed through various channels, such as hospitals, specialty clinics, online pharmacies, and retail pharmacies. Its applications include treating growth hormone deficiency and related conditions.

The increlex market consists of sales of increlex injectable solution, increlex pre-filled syringes, and increlex vials. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.